Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results

Ba‐Ssalamah, Ahmed; Matzek, Wolfgang; Baroud, S.; Bastati, Nina; Zacherl, Johannes; Schoppmann, Sebastian F.; Hejna, Michael; Wrba, Fritz; Weber, Michael; Herold, Christian; Gore, Richard M.

doi:10.1007/s00330-011-2187-2

Cited by 40 publications

(26 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T-Staging: Die MDCT ist im T-Staging in den frühen Stadien limitiert. Dennoch können unter Verwendung der "Hydro-Technik" Sensitivitäten von 95 % und ein positiver prädiktiver Wert von 96 % erreicht werden [129]. Ein T-Staging konnte in dieser Studie bei bis zu 76 % der Fälle korrekt durchgeführt werden.…”

Section: Hintergrundunclassified

S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

et al. 2019

View full text Add to dashboard Cite

Section: Hintergrundunclassified

S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

et al. 2019

View full text Add to dashboard Cite

“…In addition, we evaluated the MDCT images at portal venous phase in this study. It has been reported that the arterial phase rather than the portal venous phase can improve the accuracy of T‐staging of esophageal cancer, especially early‐staged lesions . This should be confirmed which phase should be optimal in the assessment of the distance between the esophageal tumor and the aorta in the future.…”

Section: Discussionmentioning

confidence: 92%

Distance between the esophageal tumor and the aorta measured by using the contrast‐enhanced attenuation on computed tomography for predicting this tumor invading aorta

Tsujimoto

Matsumoto

Kumano

et al. 2013

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…T and N stage were analyzed as described previously [12]. Clinical tumor stage was assessed according to the TNM classification of the Union for International Cancer Control (UICC), 6 th edition [13].…”

Section: Resultsmentioning

confidence: 99%

• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected

et al. 2018

Self Cite

View full text Add to dashboard Cite

SummaryBackgroundIn operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for predicting the effect of two different neoadjuvant chemotherapies.MethodBiomarker analysis was conducted using the mark53 analysis. Calculation of patient number needed was based on a 60% rate of marker positivity, deduced from the results of a phase II pilot study.ResultsFrom 2007–2012, the • Pancho trial recruited 235 patients with operable esophageal cancer in Austria. A total of 181 patients were eligible and could be subjected to mark53 analysis and randomization. After randomizing 74 patients, the overall TP53 mutation rate was 79%. However, due to the high prevalence of marker positivity, the number of projected patients was increased to 181 patients in order to ensure a sufficient number of marker-negative patients. After completion of the trial, the overall TP53 mutation rate was 77.9%.ConclusionDue to high medical need, the recruitment for the academic trial was excellent. Mark53 analysis clearly detected more mutations in the TP53 gene as compared to the cancer-specific p53 literature. Final analysis examining the interaction between the mark53 status and the effect of chemotherapies applied in the • Pancho trial is now awaited.

show abstract

Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results

Abstract: Using the hydro-technique and applying specific assessment criteria, MDCT appears to be an accurate, non-invasive diagnostic tool for local tumour staging of oesophageal cancer.

Cited by 40 publications

References 47 publications

S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

Distance between the esophageal tumor and the aorta measured by using the contrast‐enhanced attenuation on computed tomography for predicting this tumor invading aorta

• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected

Contact Info

Product

Resources

About